Nanosuspension Based In Situ Gelling Nasal Spray of Carvedilol: Development, In Vitro and In Vivo Characterization
- 739 Downloads
The objective of the present investigation was to develop in situ gelling nasal spray formulation of carvedilol (CRV) nanosuspension to improve the bioavailability and therapeutic efficiency. Solvent precipitation–ultrasonication method was opted for the preparation of CRV nanosuspension which further incorporated into the in situ gelling polymer phase. Optimized formulation was extensively characterized for various physical parameters like in situ gelation, rheological properties and in vitro drug release. Formation of in situ gel upon contact with nasal fluid was conferred via the use of ion-activated gellan gum as carrier. In vivo studies in rabbits were performed comparing the nasal bioavailability of CRV after oral, nasal, and intravenous administration. Optimized CRV nanosuspension prepared by combination of poloxamer 407 and oleic acid showed good particle size [d (0.9); 0.19 μm], zeta potential (+10.2 mV) and polydispersity (span; 0.63). The formulation containing 0.5% w/v gellan gum demonstrated good gelation ability and desired sustained drug release over period of 12 h. In vivo pharmacokinetic study revealed that the absolute bioavailability of in situ nasal spray formulation (69.38%) was significantly increased as compared to orally administered CRV (25.96%) with mean residence time 8.65 h. Hence, such in situ gel system containing drug nanosuspension is a promising approach for the intranasal delivery in order to increase nasal mucosal permeability and in vivo residence time which altogether improves drug bioavailability.
KEY WORDSbioavailability Carvedilol in situ gel intranasal nanosuspension
The authors are thankful to University Grant Commission (UGC), Government of India, for the research fellowship awarded and All India Council for Technical Education (AICTE-NAFETIC) for research facilities provided.
- 10.Zaki NM, Awad GA, Mortada ND, Abd. Elhady SA. Enhanced bioavailability of metoclopramide HCl by intranasal administration of a mucoadhesive in situ gel with modulated rheological and mucociliary transport properties. Eur J Pharm Sci. 2007;32(4–5):296–307. doi: 10.1016/j.ejps.2007.08.006.PubMedCrossRefGoogle Scholar
- 16.Dengning X, Peng Q, Hongze P, Hongyu P, Shaoping S, Yongmei Y, et al. Preparation of stable nitrendipine nanosuspensions using the precipitation–ultrasonication method for enhancement of dissolution and oral bioavailability. Eur J Pharm Sci. 2010;40(4):325–34. doi: 10.1016/j.ejps.2010.04.006.CrossRefGoogle Scholar
- 20.Noha MZ, Gehanne AA, Nahed DM, Seham S, Abd E. Enhanced bioavailability of metoclopramide HCl by intranasal administration of a mucoadhesive in-situ gel with modulated rheological and mucociliary transport properties. Eur J Pharm Biopharm. 2007;32(4–5):296–307. doi: 10.1016/j.ejps.2007.08.006.Google Scholar
- 22.Rowe RC, Sheskey PJ, Owen SC. Handbook of excipients. 2nd edn. UK; 2006. pp. 1120–1302.Google Scholar